Cited by 84Pregnancy and preeclampsia studiesSystemic Lupus Erythematosus ResearchReproductive System and Pregnancy

Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT

van Hoorn, Marion E., Hague, William M., van Pampus, Mariëlle G., Bezemer, Dick, de Vries, Johanna I.P.·2016·European Journal of Obstetrics & Gynecology and Reproductive Biology

Abstract

Objective To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation.Study design This multicentre randomised controlled trial was performed between December 2000 and December 2009. Women were recruited from all eight university and six non-university/teaching hospitals in The Netherlands, two university hospitals in Australia and one university hospital in Sweden. Thirty two women with a previous delivery <34 weeks gestation with HD and/or SGA and aPLA were included before 12 weeks gestation. The intervention was daily LMWH with aspirin or aspirin alone.Primary outcomes recurrent HD onset <34 weeks and recurrent HD irrespective of gestational age. Analysis by intention-to-treat.Results After an interim analysis, recruitment was ceased: accrual was low and the incidence of recurrent HD was far lower (3%) than expected (60%). The final analysis, performed on 32 women, shows no difference in the primary outcomes (LMWH and aspirin 0/16 versus aspirin only 1/16, risk difference 6.25% [CI -17 to 27%] for recurrent HD onset <34 weeks and 0/16 for LMWH and aspirin versus 2/16 for aspirin only, risk difference 12.5% [CI -15 to 35%] for HD irrespective of gestational age).Conclusion In this population of women with aPLA, who had previously had an early delivery for HD and/or SGA prior to 34 weeks gestation, combined LMWH and aspirin treatment started before 12 weeks gestation in a subsequent pregnancy did not show reduction of onset of recurrent HD either <34 weeks gestation or irrespective of gestational age, compared with aspirin alone.

Integrity signals

Registry

Crossref · 10.1016/j.ejogrb.2015.12.011

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Data from two studies showed no difference in likelihood of live births between LDA plus heparin and LDA alone in women with prior delivery before 34 weeks due to eclampsia, severe pre-eclampsia, or placental insufficiency.

    “Data from two studies (one RCT, one retrospective cohort)48 55 showed that the likelihood of live births did not differ between women treated with LDA plus heparin and those treated with LDA alone.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
van Hoorn, M. E., Hague, W. M., van Pampus, M. G., Bezemer, D., & de Vries, J. I. P.
Affiliations
  • Women's and Children's Hospital (AU)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Venue
European Journal of Obstetrics & Gynecology and Reproductive Biology
Publisher
Elsevier BV
Published
2016-02
Volume
197
Pages
168-173
ISSN
  • 0028-2243 (ISSN-L)
  • 0301-2115
OpenAlex
W2269554558
Cited by
84
References
21
Citations by year
2026: 2 · 2025: 9 · 2024: 9 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 12 · 2019: 14 · 2018: 7 · 2017: 6 · 2016: 3
FWCI
6.05
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Obstetrics & Gynecology and Reproductive Biology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
low molecular weight heparin, aspirin, antiphospholipid antibodies, hypertensive disorders of pregnancy, HELLP syndrome, preterm birth, thromboprophylaxis
MeSH terms
Adult, Aspirin, Australia, Drug Therapy, Combination, Female, Fibrinolytic Agents, Gestational Age, Heparin, Low-Molecular-Weight, Humans, Infant, Newborn, Infant, Small for Gestational Age, Netherlands, Pre-Eclampsia, Pregnancy, Pregnancy Trimester, First, Recurrence, Sweden, Antiphospholipid Syndrome, Treatment Outcome, Antibodies, Antiphospholipid, Hypertension, Pregnancy-Induced, Premature Birth, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review